TherOx, a medical device company, has presented results from the investigational device exemption (IDE) pilot study on its second-generation supersaturated oxygen (SSO2) therapy system at the 25th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium.
The SSO2 therapy IDE study results showed a 9.6% median infarct size at 30 days in high-risk patients treated with its second-generation SSO2 therapy.
The second-generation SSO2 therapy system has been designed to salvage the jeopardized myocardium and thus reduce infarct size, which correlates with improved cardiac function and mortality in heart attack patients.
The second-generation therapy system reduces the treatment time from 90 minutes to 60 minutes.
Patients who were treated with the first-generation SSO2 system in the AMIHOT II IDE study had a 20% infarct size, and control group patients treated with PCI alone had a 26.5% median infarct size.
The next-generation SSO2 system has shown great potential in improving upon the earlier successful results of the first-generation system.
TherOx president and CEO Kevin T Larkin said: "We’re very pleased with the data and we believe it moves us another step closer to our goal of providing substantially better options for treating heart attack patients."
SSO2 therapy is adjunctive to percutaneous coronary intervention (PCI) and is designed to salvage the jeopardized myocardium and thus reduce infarct size, which correlates with improved cardiac function and mortality in heart attack patients.